StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a research report released on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright lowered their target price on shares of Trevena from $9.00 to $5.00 and set a buy rating for the company in a report on Thursday, May 16th.

Trevena Price Performance

TRVN stock opened at $0.35 on Monday. The company has a fifty day simple moving average of $0.40 and a two-hundred day simple moving average of $0.53. The firm has a market capitalization of $6.50 million, a P/E ratio of -0.13 and a beta of 1.07. The company has a quick ratio of 3.60, a current ratio of 3.60 and a debt-to-equity ratio of 8.35. Trevena has a 52 week low of $0.30 and a 52 week high of $1.12.

Trevena (NASDAQ:TRVN) last released its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.01. The firm had revenue of $0.02 million during the quarter. Analysts anticipate that Trevena will post -1.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Trevena

A hedge fund recently bought a new stake in Trevena stock. Armistice Capital LLC acquired a new stake in shares of Trevena, Inc. (NASDAQ:TRVN) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned approximately 4.61% of Trevena at the end of the most recent reporting period. 13.56% of the stock is owned by institutional investors and hedge funds.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.